IGFBP4

Across TCGA pan-cancer cohorts, IGFBP4 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGFBP4’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where IGFBP4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types IGFBP4 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

PDAC, CCRCC, and HNSC are the cancer types where IGFBP4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGFBP4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Female	II,III,IV	+0.774	<.001	6	view →
CCRCC	Male	All	−0.393	<.001	6	view →
HNSC	All	IV	−0.279	.019	6	view →
LUAD	Male	III,IV	+0.289	.012	4	view →
OV	All	All	−0.794	.040	2	view →
LSCC	All	All	−0.097	.039	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGFBP4–PDAC

Open the PDAC breakdown →